» Articles » PMID: 2040013

Cotranslation of Activated Mutant P53 with Wild Type Drives the Wild-type P53 Protein into the Mutant Conformation

Overview
Journal Cell
Publisher Cell Press
Specialty Cell Biology
Date 1991 May 31
PMID 2040013
Citations 195
Authors
Affiliations
Soon will be listed here.
Abstract

Activating mutations of p53 promote tumor progression. The mutant protein adopts a characteristic conformation, which lacks the growth suppressor function of wild-type p53. We show that mutant p53 can drive cotranslated wild-type p53 into the mutant conformation: a similar effect in vivo would block wild-type suppressor function with dominant negative effect. The cotranslational effect of mutant p53 on wild-type conformation depends upon interaction between nascent polypeptides and oligomerization of the full-length proteins. We also show that oligomers of p53 proteins can be induced to change conformation in a cooperative manner. Cell growth stimulation induces a similar conformational change in p53, and our present results indicate that this may involve allosteric regulation.

Citing Articles

The Role of p53 Mutations in Early and Late Response to Mitotic Aberrations.

Hertel A, Storchova Z Biomolecules. 2025; 15(2).

PMID: 40001547 PMC: 11852650. DOI: 10.3390/biom15020244.


Misincorporations of amino acids in p53 in human cells at artificially constructed termination codons in the presence of the aminoglycoside Gentamicin.

Pawlicka K, Henek T, Uhrik L, Hernychova L, Padariya M, Faktor J Front Genet. 2024; 15:1407375.

PMID: 39563734 PMC: 11573534. DOI: 10.3389/fgene.2024.1407375.


Interaction of p53 with the Δ133p53α and Δ160p53α isoforms regulates p53 conformation and transcriptional activity.

Tomas F, Roux P, Gire V Cell Death Dis. 2024; 15(11):845.

PMID: 39562560 PMC: 11576908. DOI: 10.1038/s41419-024-07213-4.


Canonical and non-canonical functions of p53 isoforms: potentiating the complexity of tumor development and therapy resistance.

Guo Y, Wu H, Wiesmuller L, Chen M Cell Death Dis. 2024; 15(6):412.

PMID: 38866752 PMC: 11169513. DOI: 10.1038/s41419-024-06783-7.


Anticancer therapeutic strategies for targeting mutant p53-Y220C.

Chasov V, Davletshin D, Gilyazova E, Mirgayazova R, Kudriaeva A, Khadiullina R J Biomed Res. 2024; 38(3):222-232.

PMID: 38738269 PMC: 11144932. DOI: 10.7555/JBR.37.20230093.